Preparing for the unexpected: The pivotal role of social and behavioral sciences in trials of biomedical HIV prevention interventions

Journal of Acquired Immune Deficiency Syndromes

Volumn 63, Issue SUPPL. 2, 2013, Pages

  Koblin, Beryl A ^a   Andrasik, Michele ^b   Austin, Judy ^c  

^a NEW YORK BLOOD CENTER   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c Columbia University ^*  (United States)

Author keywords

Adherence; Behavioral science; Biomedical interventions; HIV; Populations; Social science

Indexed keywords

MICROBICIDE; TENOFOVIR;

ARTICLE; BEHAVIORAL SCIENCE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; PATIENT COUNSELING; PATIENT SAFETY; PRIORITY JOURNAL; SELF REPORT; SEXUAL BEHAVIOR; SOCIOLOGY; STUDY DESIGN;

AIDS VACCINES; ANTI-RETROVIRAL AGENTS; BEHAVIORAL RESEARCH; BIOMEDICAL RESEARCH; CIRCUMCISION, MALE; CLINICAL TRIALS AS TOPIC; DELIVERY OF HEALTH CARE, INTEGRATED; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; SOCIAL SCIENCES; TREATMENT OUTCOME;

EID: 84880235980     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31829a3a4d     Document Type: Article

References (48)

1. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505.
2. Auvert B, Taljaard D, Lagarde E, et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005;2:e298.
3. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007;369:643-656.
4. Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 2007; 369:657-666.
5. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367: 399-410.
6. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363:2587-2599.
7. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168-1174.
8. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361:2209-2220.
9. Flynn NM, Forthal DN, Harro CD, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005;191:654-665.
10. Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis. 2006;194:1661-1671.
11. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008;372:1881-1893.
12. STATEMENT: NIH Discontinues Immunizations in HIV Vaccine Study. Available at: http://www.niaid.nih.gov/news/newsreleases/2013/Pages/HVTN505April2013. aspx. Accessed 30 April, 2013.
13. Celum C, Wald A, Hughes J, et al. Effect of acyclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371:2109-2119.
14. Celum C, Wald A, Lingappa JR, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med. 2010;362:427-439.
15. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411-422.
16. Microbicide Trials Network. VOICE (MTN-003). 2012; Available at: http://www.mtnstopshiv.org/news/studies/mtn003. Accessed July 25, 2012.
17. Koblin BA, Mayer KH, Noonan E, et al. Sexual risk behaviors, circumcision status, and preexisting immunity to adenovirus type 5 among men who have sex with men participating in a randomized HIV-1 vaccine efficacy trial: step study. J Acquir Immune Defic Syndr. 2012;60:405-413.
18. van der Straten A, Van Damme L, Haberer JE, et al. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS. 2012;26:F13-F19.
19. Lau CY, Swann EM, Singh S, et al. Conceptual framework for behavioral and social science in HIV vaccine clinical research. Vaccine. 2011; 29:7794-7800.
20. Blair E, Burton S. Cognitive processes used by survey respondents to answer behavioral frequency questions. J Consumer Res. 1987;14: 280-288.
21. Bronfenbrenner U. The Ecology of Human Development: Experiments by Nature and Design. Cambridge, MA: Harvard University Press; 1979.
22. Gravlee CC. How race becomes biology: embodiment of social inequality. Am J Phys Anthropol. 2009;139:47-57.
23. Bane MJ, Ellwood DT. Welfare Realities: From Rhetoric to Reform. Cambridge, MA: Harvard University Press; 1994.
24. Middelkoop K, Myer L, Mark D, et al. Adolescent and adult participation in an HIV vaccine trial preparedness cohort in South Africa. J Adolesc Health. 2008;43:8-14.
25. Kapina M, Reid C, Roman K, et al. HIV incidence rates and risk factors for urban women in Zambia: preparing for a microbicide clinical trial. Sex Transm Dis. 2009;36:129-133.
26. Seage GR III, Holte SE, Metzger D, et al. Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study. Am J Epidemiol. 2001;153:619-627.
27. Ruzagira E, Wandiembe S, Abaasa A, et al. HIV incidence and risk factors for acquisition in HIV discordant couples in Masaka, Uganda: an HIV vaccine preparedness study. PLoS One. 2011;6:e24037.
28. Djomand G, Metch B, Zorrilla CD, et al. The HVTN protocol 903 vaccine preparedness study: lessons learned in preparation for HIV vaccine efficacy trials. J Acquir Immune Defic Syndr. 2008;48:82-89.
29. Koblin BA, Heagerty P, Sheon A, et al. Readiness of high-risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the United States. AIDS. 1998;12:785-793.
30. Ramjee G, Kapiga S, Weiss S, et al. The value of site preparedness studies for future implementation of phase 2/IIb/III HIV prevention trials: experience from the HPTN 055 study. J Acquir Immune Defic Syndr. 2008;47:93-100.
31. Coletti AS, Heagerty P, Sheon AR, et al. Randomized, controlled evaluation of a prototype informed consent process for HIV vaccine efficacy trials. J Acquir Immune Defic Syndr. 2003;32:161-169.
32. Buchbinder SP, Metch B, Holte SE, et al. Determinants of enrollment in a preventive HIV vaccine trial: hypothetical versus actual willingness and barriers to participation. J Acquir Immune Defic Syndr. 2004;36:604-612.
33. Feldblum PJ, Adeiga A, Bakare R, et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One. 2008;3:e1474.
34. Peterson L, Nanda K, Opoku BK, et al. SAVVY (C31G) gel for prevention of HIV infection in women: a phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS One. 2007;2:e1312.
35. Andrasik M. Social and behavioral priority areas in the HVTN. HIV Vaccine Trials Network Full Group Meeting. May 30-June 1, Washington, DC.
36. Schulz KF, Grimes DA. Blinding in randomised trials: hiding who got what. Lancet. 2002;359:696-700.
37. Schulz KF, Grimes DA. Generation of allocation sequences in randomised trials: chance, not choice. Lancet. 2002;359:515-519.
38. Bartholow BN, Buchbinder S, Celum C, et al. HIV sexual risk behavior over 36 months of follow-up in the world's first HIV vaccine efficacy trial. J Acquir Immune Defic Syndr. 2005;39:90-101.
39. Steiner MJ, Feldblum PJ, Padian N. Invited commentary: condom effectiveness-will prostate-specific antigen shed new light on this perplexing problem? Am J Epidemiol. 2003;157:298-300.
40. Orr DP, Fortenberry JD, Blythe MJ. Validity of self-reported sexual behaviors in adolescent women using biomarker outcomes. Sex Transm Dis. 1997;24:261-266.
41. Kulczycki A. In search of the holy grail: improving assessments of sexual activity in population surveys through collecting biomarkers of semen exposure. Population Association of America 2010. Available at: http://paa2010.princeton. edu/download.aspx?submissionId=101743. Accessed January 24, 2012.
42. Hochmeister MN, Budowle B, Rudin O, et al. Evaluation of prostate-specific antigen (PSA) membrane test assays for the forensic identification of seminal fluid. J Forensic Sci. 1999;44:1057-1060.
43. Mauck CK. Biomarkers of semen exposure. Sex Transm Dis. 2009;36(3 suppl):S81-S83.
44. Robb ML, Rerks-Ngarm S, Nitayaphan S, et al. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis. 2012;12:531-537.
45. Minnis AM, Gandham S, Richardson BA, et al. Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women. AIDS Behav. 2013;17:737-747.
46. Haberer JE, Kahane J, Kigozi I, et al. Real-time adherence monitoring for HIV antiretroviral therapy. AIDS Behav. 2010;14:1340-1346.
47. Microbicide Trials Network. ASPIRE-a study to prevent infection with a ring for extended use: phase III safety and effectiveness study of the dapivirine ring. 2012. Available at: http://www.mtnstopshiv.org/news/studies/ mtn020/backgrounder. Accessed May 2, 2013.
48. Wilson I, Fowler J, Cosenza C, et al. Lessons from cognitive testing of self-report adherence items. 7th International Conference on HIV Treatment and Prevention Adherence. June 3-5, 2012, Miami Beach, FL.